IFPMA 2014 interview series ‘What’s an innovation ecosystem from an industry perspective’
In this interview IFPMA President, Dr John Lechleiter, talks about vital components of the innovation ecosystem that need to be in place to bring value to patients. Dr Lechleiter discusses the need for an enabling environment that allows for greater investments in R&D through adequate incentives and efficient allocation of human and financial resources. He also underscores the need for efficient regulatory systems that are predictable, consistent, transparent, and scientifically rigorous to ensure quality, safety and efficacy of the products delivered.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.Learn more
Media ContactAbigail Jones email@example.com